StockDuty ← Dashboard Oct 25, 2026 04:40 PM ET
SignalFDA/Bio

AstraZeneca stomach cancer drug doubles survival in late-stage trial

AstraZeneca’s stomach cancer drug doubled survival in a late-stage trial.

AstraZeneca’s stomach cancer drug doubled survival in a late-stage trial.
AstraZeneca’s stomach cancer drug doubled survival in a late-stage trial. — impact context not separately stored; see What changed.
Sources